Key result
Post-transplant FDG PET and biopsy uncover systemic sarcoidosis misdiagnosed as giant cell myocarditis.
Why the study?
Giant cell myocarditis and cardiac sarcoidosis share clinical and histologic features, but whether they represent separate processes or lie on an inflammatory cardiomyopathy spectrum is unclear.
Case Report (n=1)
No
This case highlights the diagnostic challenges and overlap between giant cell myocarditis and cardiac sarcoidosis, demonstrating the utility of post-transplant FDG PET for uncovering systemic sarcoidosis in indeterminate inflammatory cardiomyopathies.
Endomyocardial biopsy alone may misclassify inflammatory cardiomyopathy; extends spectrum hypothesis linking giant cell myocarditis and sarcoidosis.
Giant cell myocarditis (GCM) and cardiac sarcoidosis share clinical and histologic features, but whether they represent separate processes or lie on an inflammatory cardiomyopathy spectrum is unclear. We present a case of cardiogenic shock thought to be secondary to biopsy-proven GCM with a subsequent post-transplant diagnosis of sarcoidosis through 18-fluorodeoxyglucose positron emission tomography and biopsy.
No takes yet. Share an insight, caveat, or question.
Fraser et al. (2024) conducted a case report in Inflammatory cardiomyopathy (Giant cell myocarditis vs Cardiac sarcoidosis) (n=1). Heart transplant and post-transplant FDG PET was evaluated. Post-transplant whole-body FDG PET imaging and lymph node biopsy revealed systemic sarcoidosis, undermining the initial pre-transplant endomyocardial biopsy diagnosis of giant cell myocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: